Skip to main content

Advertisement

SpringerLink
Log in

Drugs and Dupuytren’s disease: a pharmacovigilance study in VigiBase®

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Shih B, Bayat A (2010) Scientific understanding and clinical management of Dupuytren disease. Nat Rev Rheumatol 6:715–726

    Article  CAS  Google Scholar 

  2. No authors listed (2019) Maladie de Dupuytren causée par les médicaments. Rev Prescrire 39:826–828

    Google Scholar 

  3. Bihan K, Lebrun-Vignes B, Funck-Brentano C, Salem JE (2020) Uses of pharmacovigilance databases: an overview. Therapie 75:591–598

    Article  Google Scholar 

  4. Moore N, Berdaï D, Blin P, Droz C (2019) Pharmacovigilance - the next chapter. Therapie 74:557–567

    Article  Google Scholar 

  5. Faillie JL (2019) Case-non-case studies: principle, methods, bias and interpretation. Therapie 74:225–232

    Article  Google Scholar 

  6. Lai MC, Lin KM, Tsai JJ, Wu YJ, Huang CW (2016) Dupuytren’s Contracture: Subacute onset after long-term antiepileptic drug use. Neuropsychiatry (London) 6:366–368

    Google Scholar 

  7. Vandersleyen V, Grosber M, Wilgenhof S, De Kock J, Neyns B, Gutermuth J (2016) Vemurafenib-associated Dupuytren- and Ledderhose palmoplantar fibromatosis in metastatic melanoma patients. J Eur Acad Dermatol Venereol 30:1133–1135

    Article  CAS  Google Scholar 

  8. Khouri C, Petit C, Tod M, Lepelley M, Revol B, Roustit M, Cracowski JL (2021) Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. J Clin Epidemiol S0895–4356(21):00026–00033. https://doi.org/10.1016/j.jclinepi.2021.01.015

    Article  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the Uppsala Monitoring Centre (UMC), which provided and gave permission to use the data analyzed in the present study. The authors are indebted to the National Pharmacovigilance Centers that contributed data.

Author information

Authors and Affiliations

  1. Service de Pharmacologie Médicale Et Clinique, Centre de Pharmacovigilance, Faculté de Médecine, de Pharmacoépidémiologie Et D’Informations Sur Le Médicament, CIC INSERM 1436, Centre Hospitalier Universitaire, Toulouse, France

    Jean-Louis Montastruc, Julia Guion-Firmin, Claire de Canecaude, Genevieve Durrieu, Margaux Lafaurie & Agnès Sommet

  2. Service de Rhumatologie, Faculté de Médecine, Hôpital Purpan, Centre Hospitalier Universitaire, Toulouse, France

    Adeline Ruyssens-Witrand

Authors
  1. Jean-Louis Montastruc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia Guion-Firmin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claire de Canecaude
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adeline Ruyssens-Witrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Genevieve Durrieu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Margaux Lafaurie
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Agnès Sommet
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JLM had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. JLM did the concept and design. All authors did analysis and interpretation of data. JLM drafted the manuscript, which was critically revised and approved for its final version by all authors. No funding was required since the work was performed during the authors’ university research time with the database available without fees in the authors’ department.

Corresponding author

Correspondence to Jean-Louis Montastruc.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Disclaimer

The opinions and conclusions in this study are not necessarily those of the various centers or of the WHO or ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé, France).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Montastruc, JL., Guion-Firmin, J., de Canecaude, C. et al. Drugs and Dupuytren’s disease: a pharmacovigilance study in VigiBase®. Eur J Clin Pharmacol 77, 1587–1588 (2021). https://doi.org/10.1007/s00228-021-03139-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-021-03139-4

Search

Navigation